Precision BioSciences Inc (NASDAQ:DTIL)

6.83
Delayed Data
As of Aug 10
 -0.09 / -1.30%
Today’s Change
4.60
Today|||52-Week Range
23.67
-50.83%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$355.2M

Company Description

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.

Contact Information

Precision BioSciences, Inc.
Dibrell Building
Durham North Carolina 27701
P:(919) 314-5512
Investor Relations:

Employees

Shareholders

Mutual fund holders25.85%
Individual stakeholders12.49%
Other institutional10.64%

Top Executives

Matthew R. KanePresident, Chief Executive Officer & Director
David ThomsonChief Operating Officer
Abid AnsariCFO & Principal Accounting Officer
Jeff SmithChief Technology Officer
Derek N. JantzDirector & Chief Scientific Officer